Marianna Fontana is Professor of Cardiology and is an Honorary Consultant Cardiologist at the Royal Free Hospital, University College London, where she is Director of the UCL Cardiac MRI unit, deputy Head of Center for Amyloidosis and deputy clinical lead of the National Amyloidosis Center.

Professor Fontana obtained her Medical degree (MD) and qualifications as a cardiologist at the University of Pisa in 2011. In 2012 she obtained a BHF Clinical Research Training Fellowship to undertake a PhD at UCL which focused on CMR in cardiac amyloidosis. In 2015 she became Senior Lecturer at UCL, Honorary Consultant Cardiologist and Director of the UCL CMR unit at the Royal Free Hospital, which she founded. In 2018 Prof Fontana was awarded an Intermediate Clinical Fellowship by the BHF. She was appointed deputy Head of Center for Amyloidosis and Acute Phase Proteins and deputy clinical lead of the National Amyloidosis Center in 2019. She took up the chair of Cardiology at UCL in 2020.

Professor Fontana’s major clinical and research interests are in the delivery of efficient and effective care for patients with amyloidosis, with a particular focus on new technologies: imaging and drugs. She lectures widely in the UK and internationally on amyloidosis, and organises many multi-professional educational events. She advises industry at all stages in the lifecycle of innovative products that can help improve the life-expectancy and quality of life of patients with amyloidosis. She is the recipient of numerous awards, including the Michael Davies Early Career Award in 2021 and the BHF Fellow of the year award in 2022. She has co-authored 252 peer reviewed publications with >18000 citations (h-index 71).

Disclosures
Marianna Fontana has received research grants from Pfizer, Eidos, Alnylam, and AstraZeneca. She has provided consultancy and/or been on Advisory boards for Attralus, Alnylam, Prothena, Akcea, Pfizer, Ionis, Intellia, Alexion, Novo Nordisk, Jennsen, AstraZeneca, Lexeo, and Cardior.

Dr Sanchorawala’s research has led and defined the field in AL amyloidosis. She is recognized as one of the leading international experts and a key opinion leader in amyloidosis. With numerous publications and meeting presentations, she has been one of the pioneers in the field of clinical research in AL amyloidosis. Her work in the treatment of AL amyloidosis has been published in many peer-reviewed journals and has resulted in the evolution of the standard of care for these patients. She is currently heading many clinical trials in the treatment of AL amyloidosis. She has helped to create and cultivate the next generation of physician-scientists in the area of clinical research in amyloidosis, many of whom today play leadership roles in distinguished centers around the world.

Dr Sanchorawala serves on the executive steering committee of the Amyloidosis Research Consortium and as an associate editor of Amyloid, Journal of Protein Folding Disorders. She served as a secretary for the International Society of Amyloidosis from 2020-2022 and chair of the membership committee of the International Society of Amyloidosis from 2020-2022. She has been an invited speaker and session chair nationally and internationally.

Her influence extends beyond the groundbreaking and paradigm-shifting work in the field of amyloidosis. In addition to her scientific achievements and accolades, she is a beloved teacher, a caring mentor, and a compassionate physician with exceptional clinical acumen. She has an interest in working in charity organizations. She helps cook meals for ~300 underserved individuals at a meal center in Massachusetts (1-2 times a month) and volunteer regularly at “Cradles to Crayons” charity, non-profit organization.

Disclosures
Vaishali Sanchorawala has received research support, acted as PI for Celgene, Millennium-Takeda, Janssen, Prothena, Sorrento, Karyopharm, Oncopeptide, Caelum, and Alexion.
She has provided consultancy and/or been on Advisory boards for Pfizer, Janssen, Attralus, GateBio, Proclara, Caelum, Abbvie, Regeneron, Protego, Pharmatrace, Telix, Prothena, AstraZeneca, and Naxcella.

Laura Obici is Consultant at the Amyloidosis Research and Treatment Center, IRCCS Fondazione Policlinico San Matteo, Pavia. In February 2023 she was also appointed Head of the Rare Diseases Unit at Fondazione IRCCS Policlinico San Matteo. She was awarded her Medicine and Surgery degree with honors from the University of Pavia, Pavia, in 1994, and was later awarded a Master’s degree in molecular medicine and genetic epidemiology. In 2000, she became a specialist in internal medicine at the University of Pavia.

Dr Obici’s main research interests include the molecular mechanisms of systemic amyloidosis, the prognosis and therapy of systemic amyloidosis, and the genetic basis of hereditary amyloidosis and hereditary periodic fever syndromes.

Dr Obici was Secretary of the International Society for Amyloidosis from 2010 to 2014 and has participated as Principal Investigator/Co-investigator in twelve clinical trials of novel drugs for the treatment of hereditary amyloidosis and hereditary periodic fever syndromes. She has co-authored 195 peer-reviewed publications in international journals, including The New England Journal of Medicine, Amyloid and Journal of Molecular Biology.

Disclosures
Laura Obici has received honoraria and/or consultation fees from Pfizer, Alnylam, Astra Zeneca, Novo Nordisk, BridgeBio,and SOBI.

David Adams is Professor of Neurology at the Université Paris Saclay, and Head of the Department of Neurology (2009-2023), Centre Hospitalier Universitaire Bicêtre, at Assistance Publique-Hôpitaux de Paris,. He was Head of the French National Reference Centre for Familial Amyloidotic Polyneuropathy (FAP) and other rare peripheral neuropathies from 2005 to 2021. His clinical expertise includes peripheral neuropathies, including FAP and other rare peripheral neuropathies, and he is particularly involved in the evaluation of the effects of disease-modifying therapies on neuropathy in patients with FAP in France including liver transplantation and innovative therapies including RNAi therapies and the neurological risks of domino liver transplantation.

Professor Adams has been an Advisory Board member for the International Symposium on FAP, and also organized the first European Congress on Hereditary ATTR Amyloidosis in 2015 in Paris, and the 1st European ATTR Amyloidosis Meeting for Patients and Doctors in 2017 in Paris. He has been a board member of the Peripheral Nerve Society and the European Academy of Neurology Scientific Panel Neuropathies and Président of the French speaking of Peripheral neuropathies ((2019-2021). He was Principal Investigator in many multicentric clinical trials for FAP (AATRv-PN) including APOLLO-A, HELIOS-A.

Disclosures
David Adams has received consultancy fees from Alnylam and AstraZeneca.

Paolo Milani completed his medical training at the University of Pavia, Italy, where he later specialized in internal medicine and completed further qualifications in experimental medicine (PhD). During his PhD training he held a research fellowship role in hematology at the Mayo Clinic in Rochester, Minnesota, USA.

He is working as a clinician at the Amyloidosis Research and Treatment Center in Pavia, Italy and as an Assistant Professor in Clinical Chemistry at the University of Pavia. He is a member of a number of local and international scientific societies, including the Italian Society for Amyloidosis (currently Treasurer) and the International Society of Amyloidosis.

Dr Milani also serves as a reviewer for multiple internationally recognized journals and has authored over 110 publications focusing on the outcome prediction, treatment approaches, and diagnosis of cardiac amyloidosis.

Financial disclosures
Paolo Milani has received honoraria or consultation fees from Pfizer, Jansen, Siemens, and Prothena.

Dr Mussinelli graduated with honours at University of Pavia in 2011 and subsequently she became a specialist in Internal Medicine at the same University. She obtained the PhD diploma in Intern Medicine and Medical Therapy.

She has been working in the Amyloid Research and Treatment Center of Pavia since 2014, at first during her residency and then as a consultant from 2017. She is responsible for the cardiovascular evaluation of patients with amyloidosis. Her main research focus is the diagnosis and treatment of the different forms of cardiac amyloidosis and the management of the supportive therapy.

In 2017, she spent 6 months at the Amyloid Center at Boston University School of Medicine as a visiting researcher.

Since 2014 she is part of the International Society of Amyloidosis and a member of the Italian Society of Internal Medicine (SIMI) and American Society of Ecocardiography (ASE).

She is Sub-investigator for several ongoing clinical trials of novel drugs for the treatment of hereditary amyloidosis, wild-type TTR amyloidosis and AL amyloidosis. She has co-authored over 20 papers in international journals.

Financial disclosures
Roberta Mussinelli has participated in a company sponsored speaker bureau for Pfizer, SOBI and Alnylam.

Christine Chiti, RGN, Renal and ATTR Specialist Nurse, is currently providing comprehensive services to a wide variety of patients with ATTR Amyloidosis in the National Amyloidosis Centre. She has embarked on a new journey as a TTR specialist nurse in the National Amyloidosis Centre. She graduated as a Registered General Nurse in August 2000 with a Diploma in Nursing from Kitwe Central Hospital, Zambia.

Chiti has almost 24 years of nursing experience and worked in paediatrics and paediatric critical care, trauma, and neurology at Royal National Orthopaedic hospital, Fresenius dialysis Centres and Bart’s hospital. These posts have afforded her the opportunity to develop a well-rounded skill set with a multidisciplinary team. She firmly believes that a holistic approach is the effective way in providing quality care to patients with long term conditions.

Disclosures
Christine Chiti has participated in company sponsored speaker bureaus with Alnylam Therapeutics, Pfizer, and Astra Zeneca.